Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 63Magnetic Resonance Spectroscopy 43Carboplatin 34Cyclophosphamide 31Gemcitabine 29Cisplatin 27Biopsy 27pembrolizumab 26Radiotherapy 26Bevacizumab 25Paclitaxel 23Oxaliplatin 22Capecitabine 22venetoclax 21Standard of Care 21Injections 21Drug Therapy 21fludarabine 20Nivolumab 20Interviews as Topic 18toripalimab 17Radiosurgery 16Dexamethasone 16Blood Specimen Collection 16Azacitidine 16tislelizumab 14cemiplimab 13anlotinib 13Irinotecan 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ravulizumab × 90 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡